Alar Pharmaceuticals Inc (6785) Stock Statistics & Valuation Metrics
Total Valuation
Alar Pharmaceuticals Inc has a market cap or net worth of TWD 4.93B. The enterprise value is TWD 5.50B.
- Market Cap
- TWD 4.93B
- Enterprise Value
- TWD 5.50B
Share Statistics
Alar Pharmaceuticals Inc has 66,800,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 66,800,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Alar Pharmaceuticals Inc’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -6.94%.
- Return on Equity (ROE)
- -0.03
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- -6.94%
- Return on Capital Employed (ROCE)
- -0.07
- Revenue Per Employee
- 86.03K
- Profits Per Employee
- -2.49M
- Employee Count
- 32
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Alar Pharmaceuticals Inc is -70.18. Alar Pharmaceuticals Inc’s PEG ratio is 0.61.
- PE Ratio
- -70.18
- PS Ratio
- 1703.40
- PB Ratio
- 2.18
- Price to FCF
- -32.37
- Price to Operating Cash Flow
- -33.45
- PEG Ratio
- 0.61
Income Statement
In the last 12 months, Alar Pharmaceuticals Inc had revenue of 2.75M and earned -79.68M in profits. Earnings per share was -1.19.
- Revenue
- 2.75M
- Gross Profit
- -2.73M
- Operating Income
- -167.80M
- Pretax Income
- -78.97M
- Net Income
- -79.68M
- EBITDA
- -74.02M
- Earnings Per Share (EPS)
- -1.19
Cash Flow
In the last 12 months, operating cash flow was -154.91M and capital expenditures -2.98M, giving a free cash flow of -157.88M billion.
- Operating Cash Flow
- -154.91M
- Free Cash Flow
- -157.88M
- Free Cash Flow per Share
- -2.33
Dividends & Yields
Alar Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of 0.14%
- Dividend Per Share
- ―
- Dividend Yield
- 0.14%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.09%
- Earnings Yield
- -1.39%
Stock Price Statistics
- Beta
- 0.59
- 52-Week Price Change
- -73.16%
- 50-Day Moving Average
- 90.69
- 200-Day Moving Average
- 135.82
- Relative Strength Index (RSI)
- 25.93
- Average Volume (3m)
- 58.38K
Important Dates
Alar Pharmaceuticals Inc upcoming earnings date is Mar 09, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 09, 2027
- Ex-Dividend Date
- ―
Financial Position
Alar Pharmaceuticals Inc as a current ratio of 31.59, with Debt / Equity ratio of 0.15%
- Current Ratio
- 31.59
- Quick Ratio
- 31.59
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 24.18
- Interest Coverage Ratio
- -2071.58
Taxes
In the past 12 months, Alar Pharmaceuticals Inc has paid 712.00K in taxes.
- Income Tax
- 712.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Alar Pharmaceuticals Inc EV to EBITDA ratio is -31.93, with an EV/FCF ratio of -20.97.
- EV to Sales
- 1103.35
- EV to EBITDA
- -31.93
- EV to Free Cash Flow
- -20.97
- EV to Operating Cash Flow
- -21.37
Balance Sheet
Alar Pharmaceuticals Inc has TWD 2.28B in cash and marketable securities with TWD 1.85M in debt, giving a net cash position of TWD 2.28B billion.
- Cash & Marketable Securities
- TWD 2.28B
- Total Debt
- TWD 1.85M
- Net Cash
- TWD 2.28B
- Net Cash Per Share
- TWD 34.18
- Tangible Book Value Per Share
- TWD 35.09
Margins
Gross margin is -65.43%, with operating margin of -5708.40%, and net profit margin of -2404.27%.
- Gross Margin
- -65.43%
- Operating Margin
- -5708.40%
- Pretax Margin
- -1750.33%
- Net Profit Margin
- -2404.27%
- EBITDA Margin
- -3455.13%
- EBIT Margin
- -3662.70%
Analyst Forecast
The average price target for Alar Pharmaceuticals Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -57.57%
- EPS Growth Forecast
- -312.45%
